2022 / 05

DOI: 10.24075/brsmu.2022.054

ORIGINAL RESEARCH

The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation

Andreevskaya SN, Smirnova TG, Chernousova LN, Larionova EE, Kiseleva EA, Ergeshov A
About authors

Central Tuberculosis Research Institute, Moscow, Russia

Correspondence should be addressed: Sofia N. Andreevskaya
Yauzskaya Alleya, 2, str. 1А, Moscow, 107564, Russia; ur.liam@aifosdna

About paper

Funding: the study was conducted as part of the State Assignment № 122041100246-3 for the Central Tuberculosis Research Institute, “Intra- and Inter- species Polymorphism of Mycobacteria in Patients with Tuberculosis and Mycobacteriosis Who Receive Specific Therapy”.

Author contribution: Ergeshov A, Chernousova LN — study design; Larionova EE, Kiseleva EA — data acquisition; Smirnova TG — data analysis; Andreevskaya SN — manuscript writing, literature review; all authors contributed to the discussion.

Received: 2022-10-10 Accepted: 2022-10-24 Published online: 2022-10-31
|
  1. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
  2. Vasilyeva IA, Testov VV, Sterlikov SA. Tuberculosis Situation in the Years of the COVID-19 Pandemic – 2020-2021. Tuberculosis and Lung Diseases. 2022; 100 (3): 6–12. Russian.
  3. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
  4. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020; 128 (6): 1547–67.
  5. Miotto P, Zhang Y, Cirillo DM, Yam WC. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology. 2018; 23 (12): 1098–1113.
  6. Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One. 2015; 10 (3): e0120470.
  7. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012; 67 (4): 819–31.
  8. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med. 2009; 6 (2): e2.
  9. Siddiqi SH, Rusch-Gerdes S. MGIT procedure manual for BACTEC MGIT 960TB System. 2006.
  10. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization. 2018.
  11. Rigouts L, Miotto P, Schats M, Lempens P, Cabibbe AM, Galbiati S, et al. Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations. Sci Rep. 2019; 9 (1): 11760.
  12. Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother. 2007; 59 (5): 866–73.
  13. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014; 46 (3): 279–86.
  14. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003; 3 (7): 432–42.
  15. Batyrshina YaR, Petrenko TI, Filimonov PN. Lekarstvennaya ustoychivost' Mycobacterium tuberculosis k ftorkhinolonam v Novosibirskoy oblasti: rezul'taty populyatsionnogo issledovaniya. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2013; 15 (1): 56–65. Russian.
  16. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacincapreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2009; 47: 1767–72.
  17. Duong DA, Nguyen TH, Nguyen TN, Dai VH, Dang TM, Vo SK et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother. 2009; 53 (11): 4835–9.
  18. van Doorn HR, An DD, de Jong MD, Lan NT, Hoa DV, Quy HT et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis. 2008; 12 (7): 736–42.
  19. Ergeshov A, Andreevskaya SN, Larionova EE, Smirnova TG, Chernousova LN. The Spectrum of Mutations in Genes Associated with Resistance to Rifampicin, Isoniazid, and Fluoroquinolones in the Clinical Strains of M. tuberculosis Reflects the Transmissibility of Mutant Clones. Mol Biol (Mosk). 2017; 51 (4): 595–602. Russian.